142 related articles for article (PubMed ID: 38127829)
1. Patterns of Treatment Failure After Selective Rearranged During Transfection (RET) Inhibitors in Patients With Metastatic Medullary Thyroid Carcinoma.
Hadoux J; Al Ghuzlan A; Lamartina L; Bani MA; Moog S; Attard M; Scoazec JY; Hartl D; Aldea M; Friboulet L; Jules-Clement G; Italiano A; Besse B; Lacroix L; Baudin E
JCO Precis Oncol; 2023 Sep; 7():e2300053. PubMed ID: 38127829
[TBL] [Abstract][Full Text] [Related]
2. A Nationwide Study of Multiple Endocrine Neoplasia Type 2A in Norway: Predictive and Prognostic Factors for the Clinical Course of Medullary Thyroid Carcinoma.
Opsahl EM; Brauckhoff M; Schlichting E; Helset K; Svartberg J; Brauckhoff K; Mæhle L; Engebretsen LF; Sigstad E; Grøholt KK; Akslen LA; Jørgensen LH; Varhaug JE; Bjøro T
Thyroid; 2016 Sep; 26(9):1225-38. PubMed ID: 27400880
[TBL] [Abstract][Full Text] [Related]
3. Early, Prophylactic Thyroidectomy in Hereditary Medullary Thyroid Carcinoma: A 26-year Monoinstitutional Experience.
Pelizzo MR; Torresan F; Boschin IM; Nacamulli D; Pennelli G; Barollo S; Rubello D; Mian C
Am J Clin Oncol; 2015 Oct; 38(5):508-13. PubMed ID: 24064755
[TBL] [Abstract][Full Text] [Related]
4. RAS proto-oncogene in medullary thyroid carcinoma.
Moura MM; Cavaco BM; Leite V
Endocr Relat Cancer; 2015 Oct; 22(5):R235-52. PubMed ID: 26285815
[TBL] [Abstract][Full Text] [Related]
5. Screening of RET gene mutations in Chinese patients with medullary thyroid carcinoma and their relatives.
Wang J; Zhang B; Liu W; Zhang Y; Di X; Yang Y; Yan D
Fam Cancer; 2016 Jan; 15(1):99-104. PubMed ID: 26254625
[TBL] [Abstract][Full Text] [Related]
6. A Contemporary Review of the Treatment of Medullary Thyroid Carcinoma in the Era of New Drug Therapies.
Seib CD; Beck TC; Kebebew E
Surg Oncol Clin N Am; 2023 Apr; 32(2):233-250. PubMed ID: 36925182
[TBL] [Abstract][Full Text] [Related]
7. Classical point mutations of RET, BRAF and RAS oncogenes are not shared in papillary and medullary thyroid cancer occurring simultaneously in the same gland.
Ciampi R; Romei C; Pieruzzi L; Tacito A; Molinaro E; Agate L; Bottici V; Casella F; Ugolini C; Materazzi G; Basolo F; Elisei R
J Endocrinol Invest; 2017 Jan; 40(1):55-62. PubMed ID: 27535135
[TBL] [Abstract][Full Text] [Related]
8. Medullary Thyroid Cancer - Feature Review and Update on Systemic Treatment.
Dabelić N; Jukić T; Fröbe A
Acta Clin Croat; 2020 Jun; 59(Suppl 1):50-59. PubMed ID: 34219884
[TBL] [Abstract][Full Text] [Related]
9. Somatic RAS mutations occur in a large proportion of sporadic RET-negative medullary thyroid carcinomas and extend to a previously unidentified exon.
Boichard A; Croux L; Al Ghuzlan A; Broutin S; Dupuy C; Leboulleux S; Schlumberger M; Bidart JM; Lacroix L
J Clin Endocrinol Metab; 2012 Oct; 97(10):E2031-5. PubMed ID: 22865907
[TBL] [Abstract][Full Text] [Related]
10. Tumor Grade and Molecular Characteristics Associated with Survival in Sporadic Medullary Thyroid Carcinoma.
Censi S; Galuppini F; Clausi C; Battheu F; Manso J; Piva I; Corvaglia S; Pedron MC; Mondin A; Iacobone M; Torresan F; Merante Boschin I; Bertazza L; Barollo S; Pennelli G; Mian C
Thyroid; 2024 Feb; 34(2):177-185. PubMed ID: 38047536
[No Abstract] [Full Text] [Related]
11. RET Kinase-Regulated MicroRNA-153-3p Improves Therapeutic Efficacy in Medullary Thyroid Carcinoma.
Joo LJS; Weiss J; Gill AJ; Clifton-Bligh R; Brahmbhatt H; MacDiarmid JA; Gild ML; Robinson BG; Zhao JT; Sidhu SB
Thyroid; 2019 Jun; 29(6):830-844. PubMed ID: 30929576
[No Abstract] [Full Text] [Related]
12. High prevalence of RAS mutations in RET-negative sporadic medullary thyroid carcinomas.
Moura MM; Cavaco BM; Pinto AE; Leite V
J Clin Endocrinol Metab; 2011 May; 96(5):E863-8. PubMed ID: 21325462
[TBL] [Abstract][Full Text] [Related]
13. Genotype-specific progression of hereditary medullary thyroid cancer.
Machens A; Lorenz K; Weber F; Dralle H
Hum Mutat; 2018 Jun; 39(6):860-869. PubMed ID: 29656518
[TBL] [Abstract][Full Text] [Related]
14. Genomics and Epigenomics of Medullary Thyroid Carcinoma: From Sporadic Disease to Familial Manifestations.
Barletta JA; Nosé V; Sadow PM
Endocr Pathol; 2021 Mar; 32(1):35-43. PubMed ID: 33492588
[TBL] [Abstract][Full Text] [Related]
15. Germline RET mutation carriers in Japanese patients with apparently sporadic medullary thyroid carcinoma: A single institution experience.
Kihara M; Miyauchi A; Yoshioka K; Oda H; Nakayama A; Sasai H; Yabuta T; Masuoka H; Higashiyama T; Fukushima M; Ito Y; Kobayashi K; Miya A
Auris Nasus Larynx; 2016 Oct; 43(5):551-5. PubMed ID: 26837867
[TBL] [Abstract][Full Text] [Related]
16. Role of CDKN2C Copy Number in Sporadic Medullary Thyroid Carcinoma.
Grubbs EG; Williams MD; Scheet P; Vattathil S; Perrier ND; Lee JE; Gagel RF; Hai T; Feng L; Cabanillas ME; Cote GJ
Thyroid; 2016 Nov; 26(11):1553-1562. PubMed ID: 27610696
[TBL] [Abstract][Full Text] [Related]
17. Detection of Molecular Alterations in Medullary Thyroid Carcinoma Using Next-Generation Sequencing: an Institutional Experience.
Wei S; LiVolsi VA; Montone KT; Morrissette JJ; Baloch ZW
Endocr Pathol; 2016 Dec; 27(4):359-362. PubMed ID: 27379493
[TBL] [Abstract][Full Text] [Related]
18. Medullary Thyroid Carcinoma Associated with Germline RET
Xu JY; Grubbs EG; Waguespack SG; Jimenez C; Gagel RF; Sosa JA; Sellin RV; Dadu R; Hu MI; Trotter CS; Jackson M; Rich TA; Hyde SM; Sherman SI; Cote GJ
Thyroid; 2016 Dec; 26(12):1744-1751. PubMed ID: 27673361
[TBL] [Abstract][Full Text] [Related]
19. Correlative analyses of RET and RAS mutations in a phase 3 trial of cabozantinib in patients with progressive, metastatic medullary thyroid cancer.
Sherman SI; Clary DO; Elisei R; Schlumberger MJ; Cohen EE; Schöffski P; Wirth LJ; Mangeshkar M; Aftab DT; Brose MS
Cancer; 2016 Dec; 122(24):3856-3864. PubMed ID: 27525386
[TBL] [Abstract][Full Text] [Related]
20. Hereditary medullary thyroid carcinoma: the management dilemma.
Zhou P; Liu J; Cheng SW; Wang B; Yang R; Peng L
Fam Cancer; 2012 Jun; 11(2):157-65. PubMed ID: 22183190
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
